Diamedica Therapeutics ( (DMAC) ) has released its Q1 earnings. Here is a breakdown of the information Diamedica Therapeutics presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for acute ischemic stroke and preeclampsia, with its lead candidate DM199 being a synthetic form of the KLK1 protein.
In its first quarter 2025 financial results, DiaMedica Therapeutics reported progress in its clinical trials and provided business highlights, including upcoming results from its Phase 2 trial for preeclampsia and ongoing enrollment in its acute ischemic stroke program.
Key financial metrics revealed a net loss of $7.7 million for the quarter, with research and development expenses increasing to $5.7 million due to expanded clinical activities. The company’s cash position stood at $37.3 million, expected to support operations into the third quarter of 2026.
Strategically, DiaMedica is advancing its DM199 trials, with anticipated interim results for preeclampsia expected soon and continued progress in its ReMEDy2 trial for stroke treatment. The company is also preparing for a key opinion leader event to discuss its preeclampsia study.
Looking ahead, DiaMedica remains focused on advancing its clinical programs and expects to leverage upcoming trial data to engage with regulatory authorities, aiming to address unmet medical needs in stroke and preeclampsia treatment.